STOCK TITAN

Immunome, Inc. - IMNM STOCK NEWS

Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.

Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.

The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.

Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.

The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.

Rhea-AI Summary

Immunome has appointed Phil Tsai, PhD, as Chief Technical Officer. Tsai brings nearly 30 years of experience in product development and process optimization, notably in antibody-drug conjugates (ADCs). This strategic move comes as Immunome's pipeline progresses, including a fully enrolled Phase 3 trial of AL102 for desmoid tumors, two IND filings planned for Q1 2025, and additional ADCs in preclinical stages. Tsai's previous roles at Seagen and Pfizer underscore his proficiency in biologics and drug manufacturing. His leadership is expected to fortify Immunome's mission to develop cutting-edge cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management
-
Rhea-AI Summary

Immunome (Nasdaq: IMNM) has completed the acquisition of antibodies and related assets from Atreca for $5.5 million upfront and up to $7 million in clinical development milestones. The purchase includes rights to 28 antibodies and various materials, enhancing Immunome's ADC (antibody-drug conjugates) portfolio. Immunome's Chief Scientific Officer, Jack Higgins, emphasizes that the newly acquired antibodies align with their strategy targeting novel and unexplored cancer therapy targets. CEO Clay Siegall mentioned that this acquisition aims to expand Immunome's ADC portfolio cost-effectively and accelerate the development of innovative cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none
-
Rhea-AI Summary

Immunome (Nasdaq: IMNM) has announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Rosett, previously Executive Vice President of Operations and Interim CFO since January 2024, has played a key role in Immunome's recent strategic moves including the merger with Morphimmune and financial transactions worth over $350 million. CEO Clay Siegall emphasized Rosett's strategic insight and financial expertise as vital for advancing the company's pipeline, including the Phase 3 RINGSIDE trial of AL102 and preparing IM-1021 and IM-3050 for IND submission. Rosett's background includes senior roles at Morphimmune and experience at Research Bridge Partners, Google, and Boston Consulting Group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
management
Rhea-AI Summary

Immunome (Nasdaq: IMNM), a biotech company focused on targeted cancer therapies, reported its Q1 2024 financial results and provided a business update. The company has integrated AL102 and IM-1021 and is progressing towards regulatory submissions. Topline data for the Phase 3 RINGSIDE trial of AL102 is expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. Financially, Immunome has $309.7 million in cash and equivalents, with a runway extending into 2026. Q1 2024 expenses included $15.4 million in R&D, $112 million in in-process R&D from recent acquisitions, and $6 million in administrative costs. The company posted a net loss of $129.5 million, or $2.51 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
-
Rhea-AI Summary

Immunome, Inc. (IMNM) will be presenting at the 2024 Bank of America Healthcare Conference. The President and CEO, Clay Siegall, will present on May 15, 2024. Interested parties can access the live webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
conferences
-
Rhea-AI Summary

Immunome, Inc. (Nasdaq: IMNM) has appointed Kinney Horn as Chief Business Officer, bringing extensive experience in life sciences corporate and business development to the company. With the recent acquisition of AL102, Immunome is now a clinical stage company, aiming to enhance its development capabilities and expand its portfolio of targeted cancer therapies. Mr. Horn's successful track record in strategic partnerships will play a important role in Immunome's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
management
Rhea-AI Summary
Immunome, Inc. (Nasdaq: IMNM) appoints Dr. Sandra M. Swain, a seasoned oncology clinical researcher, to its Board of Directors. Dr. Swain's extensive experience and expertise will contribute to advancing the company's pipeline of targeted cancer therapies, including AL102 through Phase 3 and IND filings for IM-1021 and IM-3050.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
management
-
Rhea-AI Summary
Immunome, Inc. (IMNM) announces the presentation of preclinical data for IM-3050, a lead lutetium-177 radioligand therapy targeting fibroblast activation protein (FAP) at the AACR Annual Meeting 2024. The company aims to develop novel cancer therapies with improved therapeutic properties, expecting to submit an Investigational New Drug application in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Immunome, Inc. (IMNM) announces transformative year with merger, pipeline advancements, and financial results for 2023. Key highlights include the acquisition of assets, successful financing, and progress in developing targeted cancer therapies. Topline data for Phase 3 RINGSIDE trial of AL102 expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.41%
Tags
Rhea-AI Summary
Immunome, Inc. (IMNM) completes the acquisition of AL102 and AL101 from Ayala Pharmaceuticals, focusing on targeted cancer therapies. AL102, a gamma secretase inhibitor, shows promise in treating desmoid tumors, potentially setting a new standard of care. Immunome aims to advance AL102 towards Phase 1 trials, emphasizing its potential efficacy over OGSIVEO™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags

FAQ

What does Immunome, Inc. specialize in?

Immunome, Inc. specializes in developing innovative cancer immunotherapies by leveraging the human immune system's natural defenses.

What is the core technology platform of Immunome?

The core technology platform of Immunome involves utilizing highly educated immune systems from patients to discover novel antigens and native antibodies.

What are the primary focus areas for Immunome?

Immunome focuses on oncology and infectious diseases, including COVID-19, aiming to revolutionize treatment options.

Can you name some of Immunome's key pipeline assets?

Key pipeline assets include IM-1021, targeting fibroblast activation protein (FAP), and IM-4320.

Where is Immunome, Inc. based?

Immunome, Inc. is based in the United States.

What is the goal of Immunome's development strategy?

Immunome aims to establish a broad pipeline of assets that can be efficiently developed through successive value inflection points.

How does Immunome identify high-affinity antibodies?

Immunome uses a suite of high-content screening technologies to identify specific and high-affinity antibodies.

What distinguishes Immunome's approach to immunotherapy?

Immunome's approach is distinguished by leveraging patients' highly educated immune systems to discover and target novel antigens.

How does Immunome plan to impact cancer treatment?

Immunome plans to impact cancer treatment by developing therapeutics with significant potential to improve patient outcomes.

What recent achievements has Immunome made?

Recent achievements include significant milestones in research, development, and partnerships, further solidifying their leadership in antibody therapeutics.

Immunome, Inc.

Nasdaq:IMNM

IMNM Rankings

IMNM Stock Data

894.74M
59.97M
17.08%
61.52%
14.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOTHELL